Evolocumab
This injectable antibody blocks PCSK9, a protein that destroys the liver's LDL receptors, allowing more bad cholesterol to be cleared from the bloodstream. It dramatically lowers LDL cholesterol and reduces the risk of heart attack and stroke.
Áreas terapéuticas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This injectable antibody blocks PCSK9, a protein that destroys the liver's LDL receptors, allowing more bad cholesterol to be cleared from the bloodstream. It dramatically lowers LDL cholesterol and reduces the risk of heart attack and stroke.
Yes, Evolocumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2364655. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="evolocumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/evolocumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/evolocumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/evolocumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="evolocumab"></drugfyi-drug>